跳至主要内容
临床试验/NCT01704950
NCT01704950已完成不适用

Clinical Outcome of Defect Reconstruction Using IDRT Single Layer : Results From a Prospective Multicentric Trial

Integra LifeSciences Services4 个研究点 分布在 4 个国家目标入组 52 人开始时间: 2013年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
52
试验地点
4
主要终点
Rate of graft take

研究概览

简要总结

The aim of this study is to provide data and the guidelines for the use of IDRT SL in small wounds, acute and chronic (less than 6 months), showing the benefits and the easy to use of this product as a one stage procedure.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age ≥ 18 years
  • •Patient with 1 traumatic wound (burns included) or 1 reconstruction wound (oncological wounds included)
  • •Patients for whom the surgeon has recommended that an INTEGRA® SL matrix be implanted (even if the patient is not taking part in the study) with a Split Thickness Skin Graft in the same operating procedure
  • •Wound treated with only one layer of a maximum size 10cm*12.5cm

排除标准

  • •Immunosuppressed patient
  • •Chronic wound (with no healing since 6 months)
  • •Addition of any substances (growth factor, stem cells,...) in the IDRT SL during the surgery
  • •Patient with a corticoid treatment with a daily dose greater than 5 mg
  • •Patients whose life expectancy is less than 12 months
  • •Patients whose mental health or health condition (Visual deficiency, Alzheimers...) would compromise completion of the self-evaluation questionnaires
  • •Patient with an hypersensitivity to bovine collagen, chondroitin
  • •Patient with clinical signs of infection (fever, pain, colour, swelling,...) and for whom the investigator diagnosed infection

结局指标

主要结局

Rate of graft take

时间窗: Day 15 after the surgery

the mean percentage of healing expected at Day 15 after the surgery

次要结局

未报告次要终点

研究者

发起方
Integra LifeSciences Services
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验